Trials / Completed
CompletedNCT00819000
Therapy Optimization in Multiple Sclerosis (MS)
TOP MS is a Study of Multiple Sclerosis Disease Management in Collaboration With Specialty Pharmacies
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 2,878 (actual)
- Sponsor
- Teva Neuroscience, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if higher compliance and adherence rates to drug therapy for MS result in better health outcomes than lower rates of therapy compliance and adherence.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Glatiramer Acetate, IFN-beta 1a (IM), IFN-beta 1a (Subcutaneous), and IFN-beta 1b | MS therapies (listed above) used according to prescribers' instructions. |
Timeline
- Start date
- 2008-12-01
- Primary completion
- 2012-12-01
- Completion
- 2013-01-01
- First posted
- 2009-01-08
- Last updated
- 2013-01-29
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00819000. Inclusion in this directory is not an endorsement.